CN117836287A - 表皮生长因子受体抑制剂的盐和晶体形式 - Google Patents

表皮生长因子受体抑制剂的盐和晶体形式 Download PDF

Info

Publication number
CN117836287A
CN117836287A CN202280057121.2A CN202280057121A CN117836287A CN 117836287 A CN117836287 A CN 117836287A CN 202280057121 A CN202280057121 A CN 202280057121A CN 117836287 A CN117836287 A CN 117836287A
Authority
CN
China
Prior art keywords
salt
compound
crystalline
egfr
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280057121.2A
Other languages
English (en)
Chinese (zh)
Inventor
E·巴特勒
C·N·金克玛
C·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cable Chart Pharmaceutical Co
Original Assignee
Cable Chart Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cable Chart Pharmaceutical Co filed Critical Cable Chart Pharmaceutical Co
Publication of CN117836287A publication Critical patent/CN117836287A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202280057121.2A 2021-06-23 2022-06-22 表皮生长因子受体抑制剂的盐和晶体形式 Pending CN117836287A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163214089P 2021-06-23 2021-06-23
US63/214,089 2021-06-23
PCT/US2022/034550 WO2022271846A1 (en) 2021-06-23 2022-06-22 Salt and crystal forms of an epidermal growth factor receptor inhibitor

Publications (1)

Publication Number Publication Date
CN117836287A true CN117836287A (zh) 2024-04-05

Family

ID=82608408

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280057121.2A Pending CN117836287A (zh) 2021-06-23 2022-06-22 表皮生长因子受体抑制剂的盐和晶体形式

Country Status (9)

Country Link
US (1) US20240293404A1 (https=)
EP (1) EP4359400B1 (https=)
JP (1) JP2024523506A (https=)
CN (1) CN117836287A (https=)
CA (1) CA3223859A1 (https=)
ES (1) ES3042447T3 (https=)
IL (1) IL309469A (https=)
TW (1) TW202317543A (https=)
WO (1) WO2022271846A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
EP4358942A1 (en) * 2021-06-23 2024-05-01 Blueprint Medicines Corporation Pharmaceutical compositions of an epidermal growth factor receptor inhibitor
CN116554150B (zh) * 2022-12-30 2025-12-19 苏州浦合医药科技有限公司 第四代egfr抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI726968B (zh) * 2016-01-07 2021-05-11 開曼群島商Ｃｓ醫藥技術公司 Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
MX2022007969A (es) * 2019-12-23 2022-12-13 Blueprint Medicines Corp Inhibidores de egfr.
US20240058340A1 (en) * 2020-09-21 2024-02-22 The Regents Of The University Of California Compositions and methods for treating cancer
EP4358942A1 (en) * 2021-06-23 2024-05-01 Blueprint Medicines Corporation Pharmaceutical compositions of an epidermal growth factor receptor inhibitor
AR126196A1 (es) * 2021-06-23 2023-09-27 Blueprint Medicines Corp Proceso para preparar inhibidores de egfr

Also Published As

Publication number Publication date
CA3223859A1 (en) 2022-12-29
WO2022271846A1 (en) 2022-12-29
JP2024523506A (ja) 2024-06-28
ES3042447T3 (en) 2025-11-20
EP4359400B1 (en) 2025-07-02
EP4359400A1 (en) 2024-05-01
IL309469A (en) 2024-02-01
US20240293404A1 (en) 2024-09-05
TW202317543A (zh) 2023-05-01

Similar Documents

Publication Publication Date Title
CN113993590B (zh) 新型egfr抑制剂
CN106188138B (zh) 一种二氨基嘧啶化合物及包含该化合物的组合物
CN117836287A (zh) 表皮生长因子受体抑制剂的盐和晶体形式
EP3954693A1 (en) Crystal form of egfr inhibitor and preparation method therefor
JP2021073246A (ja) Ｂ−ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
CN116096710A (zh) 用于治疗braf相关疾病和障碍的4-氧代-3,4-二氢喹唑啉酮化合物
CN118221698A (zh) Kras g12d抑制剂
TWI555742B (zh) 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, The use of medicine
AU2011311814B2 (en) Substituted pyridazine carboxamide compounds
WO2020027083A1 (ja) キナゾリン化合物を有効成分とする医薬組成物
CN107540661A (zh) 作为egfr抑制剂的苯胺嘧啶化合物的结晶
CN107074778B (zh) 苯并咪唑类似物和相关方法
WO2020114388A1 (zh) 取代的吡唑并[1,5-a]吡啶化合物及包含该化合物的组合物及其用途
CN111362967A (zh) 苯并氧杂二氮杂十四碳烯衍生物及其用途
TW202400608A (zh) 雜芳族巨環醚化合物之固體形式、醫藥組合物及製備
CN117940424A (zh) Egfr抑制剂
CN110903283B (zh) 一种取代的喹唑啉类化合物、包含该化合物的药物组合物和该化合物的用途
EA018716B1 (ru) Новые 4-(тетразол-5-ил) хиназолиновые производные в качестве противораковых средств
WO2021121390A1 (zh) 杂环化合物及其药物组合物、制备方法、中间体和应用
US20240254130A1 (en) Salt and solid forms of a kinase inhibitor
HK40104230A (zh) 表皮生长因子受体抑制剂的盐和晶体形式
CN120456897A (zh) 用于治疗疾病的磷酸肌醇3-激酶(pi3k)变构色原酮抑制剂
CN118221669A (zh) 作为DNA聚合酶Theta抑制剂的衍生物
KR20250012078A (ko) 상피 성장 인자 수용체 억제제의 염 및 결정 형태
CN117836286A (zh) 用于治疗癌症的杂环egfr抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40104230

Country of ref document: HK